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Abstract
Folate coenzymes are involved in biochemical reactions of one-carbon transfer, and deficiency of 
this vitamin impairs cellular proliferation, migration and survival in many cell types. Here the 
effect of folate restriction on mammary cancer was evaluated using three distinct breast cancer 
subtypes differing in their aggressiveness and metastatic potential: non-invasive basal-like (E-
Wnt), invasive but minimally metastatic claudin-low (M-Wnt), and highly metastatic claudin-low 
(metM-Wntliver) cell lines, each derived from the same pool of MMTV-Wnt-1 transgenic mouse 
mammary tumors. NMR-based metabolomics was used to quantitate 41 major metabolites in cells 
grown in folate-free medium versus standard medium. Each cell line demonstrated metabolic 
reprogramming when grown in folate-free medium. In E-Wnt, M-Wnt and metM-Wntliver cells 12, 
29, and 25 metabolites, respectively, were significantly different (p<0.05 and at least 1.5-fold 
change). The levels of eight metabolites (aspartate, ATP, creatine, creatine phosphate, formate, 
serine, taurine and β-alanine) were changed in each folate-restricted cell line. Increased glucose, 
decreased lactate, and inhibition of glycolysis, cellular proliferation, migration and invasion 
occurred in M-Wnt and metM-Wntliver cells (but not E-Wnt cells) grown in folate-free versus 
standard medium. These effects were accompanied by altered levels of several folate-metabolizing 
enzymes, indicating that the observed metabolic reprogramming may result from both decreased 
folate availability and altered folate metabolism. These findings reveal that folate restriction results 
in metabolic and bioenergetic changes and a less aggressive cancer cell phenotype.
Implications—Metabolic reprogramming driven by folate restriction represents a therapeutic 
target for reducing the burden of breast cancer.
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Introduction
Folate coenzymes participate in biochemical reactions of amino acid conversion and 
nucleotide biosynthesis and serve as acceptors or donors of one-carbon groups (1,2). 
Metabolic pathways requiring these coenzymes include the interconversion of serine and 
glycine, degradation of glycine and histidine, biosynthesis of methionine from 
homocysteine, and biosynthesis of purine nucleotides and thymidine monophosphate (1,2). 
Folate metabolism also plays a key role in the clearance of formate generated via several 
biochemical reactions in the cell (3,4) and in mitochondrial translation initiation (2). 
Furthermore, folate pathways contribute to cellular energy production through oxidation of 
carbon groups in folate-dependent reactions (5,6), and folate can serve as an acceptor of 
formaldehyde during histone demethylation (7). Such diverse roles in metabolic processes 
make folate indispensable for normal cell function, but it cannot be synthesized by higher 
animals and must be obtained from dietary sources. Folate deficiency impairs DNA 
synthesis and repair, changes protein expression patterns and affects numerous methylation 
reactions that depend on folate for methionine/SAM biosynthesis; these effects will be 
eventually translated to deregulation of homeostasis, decreased growth rate and inhibition of 
cell division (8–10).
Metabolic reprogramming is one of hallmarks of cancer (11). Rapidly proliferating cancer 
cells are especially dependent on an abundant supply of folate to support their metabolic 
needs for limitless division, including accelerated biosynthesis of nucleotides required for 
nucleic acids (10). Moreover, folate-dependent serine and glycine synthetic pathways have 
emerged as crucial for cancer cell proliferation (12,13). Several studies indicate that 
increased serine synthesis from glucose in cancer cells is a marker of poor prognosis 
(14,15). Serine derived from this pathway donates carbon groups to the de novo purine and 
thymidine monophosphate biosynthesis, but it can be also used for ATP production; this 
folate-dependent pathway involves the conversion of serine to glycine and the glycine 
cleavage system (16). Metabolic flux through this pathway is upregulated at the level of gene 
expression in a subset of human tumors and correlates with gene signatures defining cellular 
proliferation (6).
In addition to supporting cellular proliferation, folate pathways are also required to maintain 
cellular motility, including folate-dependent regulation of tumor cell migration and invasion 
(10). Positive correlations between the migratory ability of cancer cells and folate 
supplementation, as well as the inhibitory effects of antifolates on cancer cell migration, 
have been demonstrated (17,18). Folate pathways also modulate invasiveness of prostate 
cancer cells (19) with elevated levels of folic acid promoting both growth and invasiveness 
of several prostate cancer cell lines (20). Studies from this laboratory have demonstrated that 
folate regulates motility of A549 human lung cancer cells through an effect on cofilin-
dependent actin dynamics (21). Furthermore, the cofilin-actin axis underlies the inhibition of 
metastasis and increased survival associated with dietary folate restriction in a lung cancer 
model in severe combined immunodeficient mice (22). These results are in apparent conflict 
with findings of an inhibitory effect of increased folate on invasiveness of HCT116 human 
colon cancer cells via the activation of sonic hedgehog pathways (23). The same study also 
reported increased migration of HCT116 cell treated with the antifolate methotrexate (23).
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The apparent opposite effect of folate in A549 and HCT116 cells suggests a complex 
relationship between folate restriction and cancer cell behavior. Since these cells were 
derived from lung and colon tumors respectively, they are likely to differ in many biological 
characteristics, including genetic and molecular profiles, metabolic characteristics, stem cell 
enrichment, invasiveness, and metastatic potential. To better address the biological 
characteristics contributing to the response to folate restriction, we used a series of cell lines 
derived from the same tumor that spontaneously arose in MMTV-Wnt-1 transgenic mice. 
These cell lines, defined as “epithelial (E)-Wnt”, “mesenchymal (M)-Wnt”, and metastatic 
M-Wnt to the liver (metM-Wntliver), share the same genetic background but vary in terms of 
molecular profiles, stem cell enrichment, metabolic characteristics and metastatic potential 
(24). M-Wnt and E-Wnt cells represent claudin-low and basal-like breast tumors, 
respectively according to their gene expression profiles, and recapitulated these tumors upon 
orthotopic transplantation into ovariectomized C57BL/6 mice (24). These cells classify with 
basal-like triple negative breast cancers (TNBCs), which represent ~20% of all breast 
cancers and have an especially unfavorable prognosis, high metastatic potential, and are 
refractory to targeted agents. Here we report the effect of folate on proliferation and motility 
of these cell lines and provide data on alterations in metabolic and protein expression 
profiles induced by folate restriction.
MATERIALS AND METHODS
Cell culture and reagents
Standard (2.2 μM folic acid) and folate-free RPMI 1640 media were obtained from 
Invitrogen (Carlsbad, CA). Fetal bovine serum and dialyzed fetal bovine serum were 
purchased from Atlanta Biologicals (Flowery Branch, GA). Other reagents were from Sigma 
unless otherwise indicated.
Cell lines
M-Wnt and E-Wnt cells were derived from spontaneous mammary tumors from MMTV-
Wnt-1 transgenic mice. These cell lines were tested for species verification, karyotyping and 
genomic instability, and were authenticated by the Molecular Cytogenetics Core facility at 
the University of Texas MD Anderson Cancer Center (Houston, TX). Metastatic metM-
Wntliver cells were derived from a metastatic liver lesion following orthotopic transplantation 
of previously authenticated M-Wnt cells (24).
Sample preparation for NMR metabolomics
Cells were grown for 72 h in 10-cm2 plates in either standard or folate-free medium. Plates 
at about 80% confluence were placed on ice, media removed and cells washed three times 
with ice cold PBS. After addition of 1.0 ml acetonitrile chilled to −20 °C and 750 μl ice cold 
H2O, cells were harvested by scraping and transferred into 15 ml polystyrene tube. This step 
was repeated using the same volume of acetonitrile/water to ensure that maximal number of 
cells was collected. After addition of 1.0 ml chloroform chilled to −20 °C and three small 
glass beads (3 mm diameter), cells were vigorously shaken using a vortex mixer and then 
centrifuged in swinging bucket rotor (3000xg for 20 min at 4 °C). The top aqueous layer was 
carefully transferred to 1.5 ml microcentrifuge tubes and lyophilized. The middle layer was 
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collected, dried using a SpeedVac, and the resultant pellet was weighted to assess the total 
amount of protein. All conditions were collected in triplicate.
NMR spectroscopy
Sodium phosphate buffer solution was prepared by dissolving 1,442.5 mg of NaH2PO4 and 
262.5 mg of Na2HPO4 in 100g of D2O and used without further pH correction (uncorrected 
pH meter reading 7.59; 100 mM final concentration). Water-soluble metabolite extracts were 
diluted in 550 μl of buffer containing trimethylsilylpropanoic acid (1.0 mM final 
concentration). All samples were briefly vortexed and centrifuged for 2 min at 14,000 rpm at 
room temperature and 500 μl of the resulting supernatant was subsequently transferred to 5 
mm tubes (Bruker-Biospin Corporation, Billerica, MA) for NMR analysis. All 1H- and 13C-
NMR experiments were performed at 298K on either Bruker Avance II 800 or 600 MHz 
spectrometers equipped with cryogenically cooled, triple resonance inverse (TCI) and dual 
resonance (13C-optimized) DCH cryoprobes with actively shielded Z-gradients, respectively. 
One-dimensional 1H spectra of the diluted cell extracts were collected using a Carr–Purcell–
Meiboom–Gill (CPMG) pulse sequence. All 1D experiments employed low-power pre-
saturation to suppress residual water. Typically, 1D-1H NMR spectra with a 7 s recycle delay 
were acquired with a total of 128 transients in addition to 8 dummy scans. A total of 32768 
real data points were collected across a spectral width of 15 ppm (acquisition time: 3.6 s). 
Data were zero-filled to twice the original data set size, manually phased and automatically 
baseline corrected using Topspin 3.1 software (Bruker Biospin Corporation) and the 
Chenomx NMR suite (version 8.0) program (Chenomx Inc. Edmonton, AB), respectively. A 
0.3 Hz line-broadening apodization was applied prior to spectral analysis.
NMR data analysis
The singlet produced by the known quantity of the TSP methyl groups was used as an 
internal standard for chemical shift referencing (set to 0 ppm) and for quantification. A 
targeted metabolite profiling was carried out using the Chenomx NMR suite program 
(Chenomx Inc. Edmonton, AB). All spectra were imported into the Chenomx profiling 
software and concentrations of 41 metabolites were determined. After reference 
deconvolution was applied based on the 1 mM internal TSP standard line shape, absolute 
concentrations were determined. Concentrations are expressed as the mean ± standard 
deviation (SD) of the mean. Statistical significance was determined using Student’s t-test 
without assuming a consistent SD. A p-value of <0.05 was considered significant.
Western blot and dot blot assays
Cells were lysed in RIPA buffer containing protease inhibitors cocktail (Sigma). Lysates 
were normalized by the level of total protein and analyzed by SDS-PAGE followed by 
immunoblot with corresponding antibodies. 5-Aminoimidazole-4-carboxamide 
ribonucleotide formyltransferase (AICART), 10-formyltetrahydrofolate dehydrogenase 
(ALDH1L1), phosphoribosylglycinamide formyltransferase (GART), glycine N-
methyltransferase (GNMT) and cytoplasmic C1-synthase (MTHFD1) were detected using 
in-house polyclonal antibodies (1:10000) (25–27). Polyclonal antibodies against thymidylate 
synthase (THYMS) and cytosolic serine hydroxymethyltransferase (SHMT1) (both from 
Cell Signaling Technology, 1:1000) and dihydrofolate reductase (DHFR) (Abcam, 1:1000) 
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were used. Polyclonal antibodies against methionine synthase (MTR) (1:1000) were from 
Thermo Fisher. Actin monoclonal antibody (1:5000) was from Sigma.
Cell proliferation assay
Cell viability was assessed using an MTT cell proliferation assay (Promega). Cells were 
plated at a density of 5×103 cells/well in 96-well format, and MTT was added at specified 
time points. Plates were further processed according to the manufacturer’s instructions. 
Absorbance at 570 nm was read using a Wallace 1420 multilabel counter (PerkinElmer Life 
Sciences).
Measurements of lactate and glucose
L-lactate levels were measured in cell lysate and medium using a Lactate Colorimetric 
Assay Kit (Abcam, Cambridge, MA) according to manufacturer’s instructions. Glucose 
levels in cell lysate were measured using Glucose Colorimetric Assay Kit (Abcam) 
according to manufacturer’s instructions. In these experiments, cells were grown in standard 
or folate-free medium for 0–72 h. All experiments were repeated at least two times. Data 
were normalized to final cell counts.
Transwell invasion assay
Invasion assays were carried out using inserts precoated with extracellular matrix, and the 
Cell Invasion Assay Kit (Chemicon) according to the manufacturer’s protocol. Cells were 
kept in standard or folate-free medium for 72 h and then seeded into the upper chamber of a 
Transwell insert (BD Bioscience) in serum-free medium at a density of 5×104 cells/well. 
Medium containing 10% FBS was placed in the lower chamber as a chemoattractant, and 
cells were incubated for 24 h at 37 °C in CO2 incubator. Nonmigrating cells were removed 
from the upper chamber by scraping; the remaining cells were stained with Diff-Quick dye 
(Dade Behring, Inc.). Stained cells were counted in 10 random microscopic fields in three 
independent inserts. Alternatively, stained cells were lysed with 10% acetic acid (100–200 
μl/well) and quantified by absorbance at 560 nm. In experiments with replete medium, cells 
were grown in folate-free medium for 72 h and then in medium with 2.2 μM folic acid for 72 
h.
Wound healing assay
Cells (3.5×104 cells in 70 μl) were seeded in 35-mm μ-Dish culture inserts (ibidi GmbH, 
Munich, Germany) and cultured for 24 h in standard or folate-free medium. Inserts were 
removed and images of the denuded area were taken at 0, 12, 24 and 48 h using an inverted 
microscope (Carl Zeiss, 5x magnification).
Real-time cell analysis (RTCA)
Experiments were carried out using an xCELLigence RTCA DP instrument (ACEA 
Biosciences, San Diego, CA) placed in a humidified incubator at 37°C and 5% CO2 
according to manufacturer’s manual. Cell proliferation was monitored using E-plate 16 
(ACEA Biosciences). The background impedance reading for each well was set up using 
cell-free medium (100 μl per well) after pre-incubation at room temperature for 30 min. 
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Cells were seeded in each well in 100 μl cell suspensions across a concentration range of 
5×103 to 80×103 cell/well and allowed to attach for 30 min at room temperature. Plates were 
locked in the instrument and impedance readings of each well were automatically recorded 
every 15 min for the duration of the experiment. Cell migration experiments were performed 
using two-chamber CIM-plate 16 (ACEA Biosciences). The background reading was set up 
in the absence of cells after adding serum-free RPMI 1640 medium (50 μl) in the upper 
chamber and 10% serum-containing RPMI 1640 medium (150 μl) in the lower chamber and 
incubating plates in the instrument for 60 min. Cells (40×103 in 100 μl) kept on FBS-free 
medium for 24 hours were seeded in the upper chamber and incubated for 30 min at room 
temperature. Reading was performed as for the proliferation assay.
Metabolic flux analysis
Bioenergetics of cells in the presence or absence of folate was determined using the 
Seahorse XF96 Analyzer (Agilent Seahorse Technologies, Santa Clara, CA). Cells were 
seeded at a concentration of 1×103 or 5×103 cell/well and kept in standard or folate-free 
media for 24 h or 48 h. Prior to measurement, cells were incubated with standard or folate-
free RPMI 1640 medim supplemented with 2 mM glutamine, 10 mM glucose and 1 mM 
sodium pyruvate and incubated for 1 h at 37 °C in a CO2-free atmosphere. Basal oxygen 
consumption rate (OCR) (indicative of mitochondrial respiration) and extracellular 
acidification rate (ECAR) (indicative of lactic acid extrusion following glycolysis) were 
measured. OCR and ECAR responses following administration of oligomycin (1 μM), 
carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP) (1μM), and a combination 
of antimycin (3 μM) and rotenone (3 μM) (XF Cell Mito Stress Test Kit, Agilent Seahorse 
Technologies). For glycolysis analysis, cells were incubated as above without glucose or 
sodium pyruvate and measurements were taken following administration of glucose (10 
mM), oligomycin (1 μM) and 2-deoxyglucose (50 mM) (XF Glycolysis Stress Test, Agilent 
Seahorse Technologies). Results were normalized using a bicinchoninic acid (BCA) protein 
assay (Thermo Fisher, Waltham MA). All experiments were performed in sextuplicate.
Statistical analysis
Standard errors were calculated using Microsoft Excel or GraphPad Prism. GraphPad Prism 
was used to calculate p values. Principal component analysis (PCA) was carried out in the 
programming language R to reduce the dimension of the metabolic profile of each cell line. 
The first two principal components, i.e. PC1 and PC2, are displayed. In the PCA analysis, 
the cell line data was first mean-centered and subsequently the PCs were computed. The 
mean-centered data was not further scaled to obtain the z-score before the computation of 
the PCs.
RESULTS
Levels of major metabolites in Wnt cells
We performed targeted metabolic profiling of E-Wnt, M-Wnt and metM-Wntliver cells using 
NMR spectroscopy. This approach allowed us to detect and identify 41 major metabolites, 
including 15 common amino acids (Table 1). The number of analyzed metabolites in these 
experiments was limited essentially by the sensitivity of the NMR-based detection, which 
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was about 1 μM, in combination with the regional complexity of the NMR spectrum. 
Principal Component Analysis (PCA) was carried out to compare metabolic profiles of three 
cell lines. This mathematical method allows evaluation of differences between large data sets 
(levels of 41 compounds for each cell line in our case) upon the reduction of variables to a 
smaller number (“principal components”) and is commonly used for the analysis of 
metabolomic data (28,29). PCA has shown that, based on the overall metabolic signature, 
samples from the three cell lines are well segregated indicating that these cell lines are 
metabolically different (Fig. 1A). Most differences were between the epithelial E-Wnt cell 
line and the two mesenchymal cell lines (M-Wnt and metM-Wntliver). Levels of eight 
metabolites (4-aminobutyrate, aspartate, creatine phosphate, glucose, NAD+, proline, 
taurine, and β-alanine) were approximately two-fold or more higher and levels of two 
metabolites, glycine and putrescine, were approximately two-fold lower in E-Wnt cells 
compared to M-Wnt or metM-Wnt cells (Table 1). In addition, levels of ATP, NAD+ and 
NADP+ were higher in the E-Wnt cells relative to M-Wnt or metM-Wntliver cells (Table 1).
Alterations in major metabolites in response to folate restriction
Significant changes in response to folate restriction were observed in each of the cell lines 
with generally stronger effects on mesenchymal cells than epithelial cells (Table 1). PCA 
performed for metabolic profiles of cells growing in standard (control) versus folate-free 
medium demonstrated clear and strong treatment-dependent segregation in each case (Fig. 
1B), which we interpreted as metabolic reprogramming. Statistically significant changes 
(p<0.05) in levels of 12 metabolites occurred in E-Wnt cells as compared with 29 and 25 
metabolites, respectively, in M-Wnt and metM-Wntliver cells (Table 1). Eight metabolites 
(aspartate, ATP, creatine, creatine phosphate, formate, serine, taurine and β-alanine) were 
changed in all cell lines, with five of them (aspartate, ATP, creatine, serine and taurine) 
altered in the same direction in each cell line (Table 1). Between M-Wnt and metM-Wntliver 
cells, 22 metabolites were commonly changed with 20 of them altered in a similar way (up 
or down) and two metabolites (creatine phosphate and β-alanine) changed differently (Table 
1 and Fig. 1C).
Statistically significant elevations in serine and myo-inositol, and reductions in creatine and 
taurine, were detected in all cell lines after folate restriction (Table 1 and Fig. 1C). Taurine 
and serine were changed to about the same extent in all cells; changes in myo-inositol were 
less prominent in E-Wnt cells while levels of creatine decreased more in E-Wnt cells than in 
M-Wnt or metM-Wntliver cells (Table 1 and Fig. 1C). Most amino acids with the exception 
of glycine were elevated in cells grown on folate-free media (Table 1 and Fig. 1C). This 
trend had a higher magnitude in two mesenchymal cell lines (Fig. 1C). In mesenchymal 
cells, strong accumulation of glucose was observed with concomitant drop in lactate upon 
folate restriction, while levels of glucose was not changed in epithelial cells with only 
marginal decrease of lactate levels (Table 1 and Fig. 1C). Overall, clustering of samples after 
PCA has shown that following folate restriction both mesenchymal cell lines were very 
different metabolically from epithelial E-Wnt cells but were indistinguishable from each 
other (Fig. 1A).
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Changes in folate enzymes
Using Western blot assays, we evaluated changes in levels of several key folate enzymes in 
response to folate starvation. No noticeable increase in the levels of any of tested folate 
enzyme was observed while cell type-specific down regulation of several targets was 
apparent after folate withdrawal (Fig. 2A). Levels of several enzymes were not changed in 
Wnt cells, including TYMS, MTR, and the folate-dependent enzyme in the de novo purine 
biosynthesis, AICART (Fig. 2A). Another folate-dependent enzyme in the de novo purine 
pathway, GART, was noticeably down-regulated in each cell line (Fig. 2A). Dihydrofolate 
reductase (DHFR), the key enzyme to convert dietary folic acid to tetrahydrofolate, was 
down-regulated in mesenchymal type cells (M-Wnt and metM-Wntliver) but not epithelial E-
Wnt (Fig. 2A). Conversely, strong decreases in levels of MTHFD1 and SHMT1 were 
observed in E-Wnt cells with no changes for the latter protein and marginal changes in the 
former protein in M-Wnt and metM-Wntliver cells (Fig. 2A). Two folate enzymes, 
ALDH1L1 and GNMT, were not detected in any of the three cell lines (Fig. 2A), which is in 
agreement with the reported ubiquitous loss of these proteins in malignant tumors (25,27). 
Western blot data were confirmed by dot-blot assays (Supplementary Fig. 1), which allows a 
more robust assessment of proteins levels using triplicates of multiple sample dilutions to 
both increase accuracy and ensure that observed differences were not the result of sample 
variations. Reactions catalyzed by corresponding enzymes are depicted in Fig. 2B.
Metabolic flux analysis
Alterations in intracellular glucose and lactate levels in response to folate restriction were 
assessed using colorimetric assays and indicated the impairment of glycolysis. In cells 
maintained in a standard culture medium, both intracellular and extracellular levels of lactate 
increased in time-dependent manner (Fig. 3). In contrast, both intracellular and extracellular 
lactate levels were decreased if cells were cultured in folate-free media (Fig. 3). Likewise, 
compared to cells grown in control (standard) media, glucose levels were increased in M-
Wnt and metM-Wntliver (but not E-Wnt) cells grown in folate-free medium (Fig. 3). These 
results were consistent with NMR metabolomic profiling experiments (Table 1 and Fig. 1C). 
We further used a Seahorse metabolic analyzer to examine metabolic flux in cells grown in 
standard or folate-free medium. We observed that folate depletion resulted in significantly 
decreased oxygen consumption rate (OCR) in E-Wnt, M-Wnt and metM-Wntliver cell lines 
(Fig. 4). Inhibition of ATP synthase with oligomycin (mitochondrial stress test) and 
incubation with mitochondrial uncoupler FCCP demonstrated that folate depleted cells 
display reduced ATP production and reduced maximal mitochondrial respiration, as well as 
reduced respiratory capacity (the difference between maximal and basal OCR) (Fig. 4). 
Folate restriction also caused a significant reduction in glycolysis, as measured by 
extracellular acidification rate (ECAR) following stimulation with glucose (Fig. 4). In 
addition, all cell lines displayed reduced maximal glycolysis rate following incubation with 
oligomycin, and decreased glycolytic reserve (the difference between maximal and glucose 
stimulated ECAR) (Fig. 4). Overall, our data indicated the impairment of both mitochondrial 
respiration and glycolysis upon folate withdrawal from culture medium. Of note, the effect 
of folate restriction was stronger in M-Wnt and metM-Wntliver cells than in E-Wnt cells 
(Fig. 4).
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Proliferation and migration of Wnt cells
To investigate how the observed metabolic reprogramming following folate restriction 
influences cellular behavior, we evaluated the effect of folate withdrawal on cellular 
proliferation, invasion and migration. All three tested cell lines, E-Wnt, M-Wnt and metM-
Wntliver were sensitive to the loss of folate: proliferation was essentially arrested by 48 h of 
folic acid withdrawal from the media (Fig. 5A). Significant cell death was observed if cells 
were cultured without folate for more than 72 h (data not shown). As assessed by the 
transwell assay, folate restriction (72 h in folate-free medium) strongly inhibited cell 
invasion with a more profound effect observed in M-Wnt cells than either E-Wnt or metM-
Wntliver cells (Fig. 5, B and C). This inhibitory effect was reversible upon repletion of cell 
culture medium with folic acid (Fig. 5, B and C). Wound healing scratch assays further 
indicated that the migration of Wnt cells was strongly inhibited in the absence of folate 
(Supplementary Fig. 2). We have also measured cellular migration using impedance-based 
ACEA technology (30). The setup in this approach corresponds to the conventional 
transwell assay but allows the constant monitoring of migration in real time and minimizes 
the input of cell proliferation. The real-time monitoring of cellular migration confirmed that 
folate restriction more strongly affected migration of cells with mesenchymal (M-Wnt and 
metM-Wntliver) relative to epithelial (E-Wnt) phenotype (Fig. 5, D–F). Similar to invasion, 
the effect of folate restriction on migration was reversible: cells restored their proliferation 
and migration capacity after folate in medium was replete (data not shown).
DISCUSSION
Folate is involved in several major metabolic processes (Fig. 2B), and modulation of folate 
levels has a pleiotropic effect on the cell, directly or indirectly influencing levels of 
numerous metabolites (pathways connecting folate metabolism to metabolites altered in our 
study are depicted in Fig. 6). Targeting folate metabolism using antifolates such as 
methotrexate and aminopterin was one of the earliest cancer chemotherapeutic approaches 
(31). However, antifolates, and more recently specific inhibitors aimed at counteracting 
upregulation of key biosynthetic/salvage enzymes involved in folate metabolism, are 
typically quite toxic and prone to inducing tumor cell resistance (31). Folate restricted diets 
have been suggested as a possible alternative to pharmacologic antifolate agents, but the 
limited studies to date regarding breast cancer have shown both enhancing and inhibitory 
effects of low-folate diets and suggest factors such as tumor stage and molecular subtype can 
influence the effect of folate restriction on breast cancer. To begin to deconvolute the 
complex relationship between folate restriction and breast cancer, we assessed folate 
restriction effects on mammary cancer cell lines (derived from MMTV-Wnt-1 transgenic 
mouse mammary tumors) with differential metastatic potential and molecular characteristics. 
Cells representing basal-like (epithelial type E-Wnt cell line) and claudin-low (mesenchymal 
M-Wnt and metM-Wntliver cell lines) breast tumors were analyzed. We found that folate-free 
medium, compared to standard medium containing 2.2 μM folic acid, induced changes in 
several metabolites (serine, glycine, histidine, formate and taurine) and decreased some key 
folate enzymes involved in metabolism of serine, glycine and formate and supporting the 
flux of one-carbon groups to the intracellular folate pool. Significant changes in levels of 
glucose and several metabolites derived from glucose were observed in mesenchymal (M-
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Wnt and metM-Wntliver) cells but not in epithelial E-Wnt cells. Folate restriction also 
strongly inhibited glycolysis in M-Wnt and metM-Wntliver cells in association with 
inhibition of cellular proliferation, migration and invasion. Overall, our findings indicated 
that folate restriction can initiate cell type-specific metabolic reprogramming of breast 
cancer cells towards a less aggressive phenotype.
Based on metabolic pathways of folate (1,2), the immediate downstream effects of altered 
levels of folate should be on serine, glycine, histidine, methionine, homocysteine, formate 
and nucleotides (Fig. 2B). Interestingly, we have observed that overall levels of amino acids 
in folate-starved cells are increased, though this increase is marginal in E-Wnt cells (Fig. 
1C). We have interpreted this effect as an indication of decreased protein synthesis, 
consistent with the antiproliferative effect of folate restriction observed in the three studied 
cell lines. While levels of most amino acids were elevated upon folate restriction, levels of 
glycine were only marginally elevated in M-Wnt cells but decreased in two other cell lines. 
This finding is in agreement with the deficiency of folate coenzymes, which would prevent 
the generation of glycine from serine. It should be noted that the consumption of 
extracellular glycine is not sufficient to support metabolic needs of cancer cells (32). 
Furthermore, strong elevation of serine, as well as the elevation of histidine and formate 
(Table 1 and Fig. 1C), fit the signature of folate deficiency. The drop in ATP observed in 
folate-starved cells conforms with recent findings that folate pathways contribute to cellular 
energy production (5,6). This ATP reduction was less profound in E-Wnt cells, possibly due 
to input of activated phosphate groups from creatine phosphate. Indeed, a significant 
decrease in creatine phosphate upon folate withdrawal was measured in E-Wnt cells but not 
M-Wnt or metM-Wntliver cells (Table 1). While the replenishment of ATP by creatine 
phosphate is a well-known phenomenon, the capacity of this process in M-Wnt and metM-
Wntliver cells might be insufficient due to low levels of creatine phosphate in these cells.
Levels of several metabolites not directly relevant to folate pathways were significantly 
changed upon folate restriction. Of particular interest was the drop in lactate with 
simultaneous elevation of glucose, a phenomenon observed only in mesenchymal M-Wnt 
and metM-Wntliver cells but not E-Wnt cells. In many tumor types high lactate production 
and concentration have been associated with increased migratory ability and invasiveness of 
cancer cells, more aggressive cancer stages, and metastasis (33,34). While changes in 
metabolites not associated directly with folate metabolism could be a consequence of 
inhibited proliferation, at least in case of lactate our results suggest otherwise. Thus, strong 
difference in levels of lactate between cells grown in standard versus folate-free medium 
were recorded at time points when proliferation was not yet arrested (compare Figs. 3 and 
5A).
One advantage of a high glycolytic rate in cancer cells is the acidification of the tumor 
microenvironment by lactate extrusion, which is associated with higher proliferation, 
migration and invasion, angiogenesis and increased cell survival (35). For example, the 
decrease of lactate production by knocking down lactate dehydrogenase inhibits migration 
and invasion of 4T1 breast cancer cells (36). Similar effects were demonstrated in several 
cancer cell lines by targeting lactate transporters (37,38). Lactate may also serve as a 
signaling molecule in breast cancer regulating nutrient uptake and potentially cell viability, 
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proliferation and migratory capacity (39). In addition, through the conversion to pyruvate 
lactate can be used for energy generation, particularly in breast tumors (33,40). Thus, within 
the same tumor, lactate produced by glycolytic tumor cells can be consumed by oxidative 
tumor cells for the energy generation (41). In our study the drop in lactate in folate-deficient 
cells was not associated with increased lactate excretion since the extracellular 
concentrations of this metabolite were also significantly decreased. While such a drop could 
be associated with enhanced lactate utilization for the energy production, the accumulation 
of glucose in folate-deficient cells was in agreement with the decreased lactate generation. 
Likewise, metabolic profiling using Seahorse technology indicated reduced glycolytic 
capacity in folate-starved cells with stronger effect on mesenchymal (M-Wnt and metM-
Wntliver) cells.
In recent years numerous studies have attempted to use metabolomic data to define a 
signature for tumorigenic potential of different malignancies, including breast tumors (42). 
Lactate, taurine, glucose and myo-inositol have been linked with tumor aggressiveness, 
although precise associations between their levels and disease need further clarification 
(34,42,43). Interestingly, changes of these four metabolites in folate deficient versus folate 
supplemented M-Wnt and metM-Wntliver cells (Fig. 1C) mirror the pattern of their 
alterations in colorectal cancer, where glucose and myo-inositol are decreased while lactate 
and taurine are increased compared to normal tissues (34). Specifically to myo-inositol, it 
has been also reported that this metabolite was significantly increased in breast cancer 
survivors who underwent chemotherapy (44) and in healthy control subjects compared to 
men with prostate cancer (45). These findings suggest that the drop in myo-inositol levels is 
a common trend in malignancies. Accordingly, significantly increased levels of myo-inositol 
in folate-restricted cells imply a shift towards less aggressive phenotype, which is in 
agreement with the loss of migratory and invasive ability in these cells. While it is unclear 
how folate restriction results in the elevation of myo-inositol, this elevation was 
accompanied by an elevation of glucose, the substrate for myo-inositol biosynthesis (46). 
Levels of taurine, which in our study significantly decreased with folate restriction, have 
been used in several studies as a tumor marker (43,47–49). Relevant to our study, levels of 
taurine increased in breast cancer biopsies (50) yet decreased in MCF-7 breast cancer cells 
treated with curcumin, a compound with known antiproliferative activity (51). Thus, 
decreased taurine levels in response to folate restriction may be indicative of an overall 
antiproliferative effect. Interestingly, while creatine levels were decreased in all cell lines, a 
much greater decrease occurred in E-Wnt cells. To the best of our knowledge, creatine levels 
have not previously been investigated with regard to folate status. Creatine synthesis, 
however, might have connections to folate metabolism: glycine and SAM, required for this 
pathway could originate from folate metabolism (Fig. 6).
The observed changes in the pattern of major metabolites in response to folate restriction 
were associated with the strong inhibition of cellular proliferation, migration and invasion of 
mammary cancer cells. The immediate effect of folate restriction on cellular processes most 
likely is associated with the direct input on specific folate-dependent biochemical reactions. 
Thus, recent studies underscore a link between folate-dependent serine and glycine 
metabolism, and cellular proliferation, migration and overall aggressiveness of tumors 
(6,32,52). Further down-stream effects could be mediated by alterations in the protein 
Ashkavand et al. Page 11
Mol Cancer Res. Author manuscript; available in PMC 2018 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
expression profile, a phenomenon reported previously for folate deficiency (53). In our 
study, folate restriction led to the decrease of levels of some folate enzymes with a more 
strong effect observed for SHMT1 and MTHFD1 in E-Wnt cells. Of note, MTHFD1 has 
previously been linked to melanoma metastasis (54). While the effect of folate withdrawal 
can perhaps be additionally mediated by alterations of folate enzymes, we suggest that the 
primary effect on cellular metabolite is due to the direct input on folate-dependent reactions. 
Overall, we conclude that restriction of folate in mammary cancer cells reprograms cellular 
metabolism towards a less proliferative or migratory phenotype, with a more profound effect 
exerted in cells with a mesenchymal, relative to an epithelial, phenotype. Folate restriction-
related metabolic reprogramming may therefore represent a therapeutic target for reducing 
the burden of breast tumors that have undergone EMT, such as claudin-low breast cancers.
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Figure 1. 
Metabolic profiling of cells grown in standard (2.2 μM folic acid) or folate-free medium. A. 
Principal component analysis (PCA) for metabolites measured in Wnt cells by NMR 
spectroscopy shows how metabolically distinct are corresponding cell lines when grown in 
standard (left panel) or folate-free (right panel) medium. There is a good separation between 
cell lines when they grow in standard medium but M-Wnt and metM-Wntliver cell lines 
become metabolically indistinguishable when grown in folate-free medium. A total of 41 
metabolites were measured for each of the cell lines. In order to visualize the metabolic 
profiles of different cell lines, principal component analysis (PCA) was carried out in the 
programming language R to reduce the dimension of the metabolic profile of each cell line. 
The first two principal components, i.e. PC1 and PC2, are displayed. In the PCA analysis, 
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the cell line data was first mean-centered and subsequently the PCs were computed. The 
mean-centered data was not further scaled to obtain the z-score before the computation of 
the PCs. Ellipses are the confidence regions for the corresponding group of cell types B. 
PCA shows strong differences in the metabolic profile for each cell line grown in standard 
vs. folate-free medium. C. Metabolites most significantly altered in Wnt cells after folate 
withdrawal (fold change calculated from Table 1 is shown). Dashed lines designate a 
threshold of 1.5-fold. AA, total amino acids; UDP-Glc, UDP-glucose; m-Inos, myo-inositol.
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Figure 2. 
Levels of folate enzymes in Wnt cells. A. Western blot assays of the level of cytosolic folate 
enzymes in Wnt cells grown in standard (control, C) or folate-free (FF) media for 72 h. 
metM, metM-Wntliver cells. B. Schematic depicting folate pathways and reactions catalyzed 
by enzymes evaluated in panel A. FA, folic acid; DHF, dihydrofolate; THF, tetrahydrofolate; 
5mTHF, 5-methyl-THF; 10fTHF, 10-formyl-THF; HCys, homocysteine; Sarc, sarcosin. 
Enzymes catalyzing corresponding reactions are shown in grey ovals. AICART, 5-
aminoimidazole-4-carboxamide ribonucleotide formyltransferase; ALDH1L1, cytosolic 10-
formyltetrahydrofolate dehydrogenase; DHFR, dihydrofolate reductase; GART; glycinamide 
ribonucleotide formyltransferase; GNMT, glycine N-methyltransferase; MTHFD1, cytosolic 
C1-synthase; MTHFR, methylenetetrahydrofolate reductase; MTR, methionine synthase; 
SHMT1, cytosolic serine hydroxymethyltransferase; TYMS, thymidylate synthase.
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Figure 3. 
Levels of glucose and lactate in E-Wnt, M-Wnt and metM-Wntliver cells grown in standard 
or folate-free medium were measured by calorimetric assays. Measurements were performed 
in duplicates (averages are shown).
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Figure 4. 
Effect of folate restriction on mitochondrial respiration (oxygen consumption rate, OCR) 
and glycolysis (extracellular acidification rate, ECAR) of Wnt cells. A Seahorse metabolic 
analyzer was used to examine metabolic flux in cells. Differences for OCR between cells 
grown in standard and folate-free (FF) media were statistically significant (p<0.001). 
Differences for ECAR were statistically significant for E-Wnt and metM-Wntliver cells 
(p<0.05); for M-Wnt cells p<0.14.
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Figure 5. 
Effect of folate withdrawal on proliferation, invasion and migration of Wnt cells. A. Cell 
proliferation was evaluated by MTT assay. (B) Invasion was evaluated by transwell assay 
after cells were grown in folate-free medium for 72 h. In control experiments cells were kept 
in a standard (2.2 μM folic acid) medium. In experiment with replete folate cells were kept 
in folate-free medium for 72 h and then grown in standard medium for 72 h. Pictures show 
cells, which traversed through matrix. C. Calculation of cells traversed through the 
extracellular matrix (based on absorbance at 560 nm after staining with Diff-Quick dye). D–
F. Real-time monitoring of cellular migration using xCelligence instrument. Cell index 
reflects cellular migration. Experiments were performed in duplicate with automatic 
averaging of reading from two wells. FF, folate-free medium.
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Figure 6. 
Schematic depicting pathways of metabolites altered in response to folate restriction. The 
bottom box highlights pathways directly or indirectly associated with folate metabolism and 
thus expected to be responsive to folate restriction. The connection between glucose and 
folate metabolism is not yet established (upper box). FA, folic acid; THF, tetrahydrofolate; 
C1, one-carbon group; HCys, homocysteine.
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